Tag: sees-potential
-
French drug developer Pharnext to take rare approach to pricing
A privately held French drug developer is taking a rare approach to pricing its drug intended to treat a rare disease. Pharnext SAS, whose drug is the only treatment in a late-stage trial for treating a rare inherited disorder called Charcot-Marie-Tooth (CMT), sees potential to earn a healthy profit by selling the yet-to-be approved drug…
-
French drug developer Pharnext to take rare approach to pricing
A privately held French drug developer is taking a rare approach to pricing its drug intended to treat a rare disease. Pharnext SAS, whose drug is the only treatment in a late-stage trial for treating a rare inherited disorder called Charcot-Marie-Tooth (CMT), sees potential to earn a healthy profit by selling the yet-to-be approved drug…
-
General Mills meets sodium-reduction goal in seven of ten product categories
By Anjali Athavaley NEW YORK (Reuters) – General Mills Inc said on Tuesday that it had reduced sodium by at least 20 percent in seven product categories, fewer than it had targeted, as part of the food industry’s effort to cut back on an ingredient said to increase the risk of serious illnesses. The maker…